Actuate Therapeutics Reports Phase 2 Trial Success for Elraglusib in Metastatic Pancreatic Cancer
I'm PortAI, I can summarize articles.
Actuate Therapeutics Inc. reported successful Phase 2 trial results for elraglusib in metastatic pancreatic cancer, presented at the 2026 ASCO GI Symposium. The trial met its primary endpoint, showing a 38% reduction in death risk compared to standard chemotherapy, with improved overall survival. As of November 2025, 17 patients in the elraglusib group remain alive, including three who have exceeded 24 months of survival, while no patients on chemotherapy alone are alive.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments